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Hybrid capture is an easy and highly sensitive technique for screening population due to its capacity to
detect malignant and premalignant lesions of the cervix. To evaluate its sensitivity, we investigated the
frequency of high-risk human papillomavirus (HPV) infection and its correlation with glandular malignant
lesions, analyzing a total of 113 cases of adenocarcinomas and related lesions. High-risk HPV was investi-
gated using a hybrid capture II (HC2) assay. Samples were collected in two different ways: either brushed
directly from surgical specimens before fixation or collected from the patients. We also investigated the fre-
quency of HPV in squamous malignant lesions, 65 squamous cell carcinomas (SCC) and 66 in situ squa-
mous cell carcinomas (ISSCC), to compare the occurrence of HPV for these lesions. The 113 glandular
lesions comprised 62 invasive adenocarcinomas (IAC), 8 in situ adenocarcinomas (ISAC), 26 IAC plus SCC,
and 17 adenosquamous cells carcinomas (ASCC). The HPV-positive reactions were as follows: 51 (82.2%) in
IAC, 8 (100%) in ISAC, 25 (96.1%) in IAC plus SCC, and 14 (82.3%) in ASCC. HC2-positive results in the
squamous malignant lesions were as follows: 58 of 63 (89.0%) for SCC and 94 of 103 (91.2%) for ISSCC.
High-risk HPV infection was quite similar for glandular and pure squamous invasive malignant lesions,
82.2% and 89.0%, respectively, indicating that high-risk HPV is also highly prevalent in glandular lesions.
Although hybrid capture proved to be an excellent adjunctive technique, we do not believe its results merit
replacing the Pap smear as a screening tool.
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Cervical cancer is distributed throughout the world,
afflicting 500,000 women annually. The most impor-
tant risk factor for the development of this condition is
the human papillomavirus (HPV) infection. It is
believed that 80% of primary cancers begin from
preexisting squamous dysplasia. With respect to glan-
dular epithelium malignancies, adenocarcinomas ac-
count for about 20% of invasive carcinomas, which
probably arise from in situ adenocarcinomas (ISAC)(1).
Interestingly, the incidence of adenocarcinoma is
increasing mainly in developed countries(1,2), and it is
currently thought to be more significant in large cities
due to the increased probability of HPV infections.
Glandular malignant lesions, namely, ISAC, are fre-
quently overlooked because clinical, colposcopic, and
cytologic parameters are unfamiliar and bypassed by
concomitant squamous alterations. Additionally, more
than 50% of ISAC are mixed diseases with a squamous
lesion counterpart(3). Indeed, traditional methods have
poor sensitivity to detect precursor lesions of glandular
carcinomas. HPV status has a significant impact when
correlated with age at diagnosis but not cytology(4).
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Cytology is poorly reproducible for ISAC diagnoses
because of its high rates of false-negative results(5).
High-risk HPV status in ISAC, coexisting or not with
high-grade intraepithelial lesion (HSIL), seems to be dif-
ferent. The frequency of high-risk HPV genotypes is simi-
lar in patients with ISAC alone and with ISAC coexisting
with HSIL but significantly different for patients with
HSIL without ISAC(6). The distribution of HPV types de-
tected in invasive squamous cell carcinomas (SCC) and
adenocarcinoma (AC) was found to be also different and
probably associated with variable cofactors(7).
For high-grade squamous lesions, the sensitivity of
testing DNA-HPV is superior to cytology but less spe-
cific(8). However, HPV-DNA typing is very useful as
an adjunct in distinguishing endocervical and endome-
trial adenocarcinoma(9) and, in combination with cytol-
ogy, in the follow-up of patients treated for HSIL(10).
Under routine conditions with liquid-based cytology,
hybrid capture II (HC2) assay has enhanced sensitivity
when compared to in situ hybridization(11) for detect-
ing HPV infection. DNA-HPV–positive cases in atypi-
cal glandular cells of undetermined significance, as
determined by polymerase chain reaction (PCR) or
HC2, have a significant negative predictive value and
a higher positive predictive value for significant dis-
ease than atypical squamous cells(12). Actually, HPV
testing for atypical glandular cells is strongly recom-
mended for management of these patients(13).
Prognostic factors in uterine cervix adenocarcinoma
have been recently revised. Longest survival is found
for patients with disease in its early stages, of younger
age, and after primary surgery(14). Otherwise, mitotic
and apoptotic indexes, and the ratio of both, correlate
adenocarcinoma to patient survival(15).
Currently, it is thought that by adding high-risk
HPV testing to cervical screening, the invasive adeno-
carcinomas (IAC) and ISAC frequently missed in pop-
ulation-based screening programs might be enhanced.
Additionally, the identification of a number of proteins
related to HPV infection has also improved the com-
prehension of some biologic events involved in adeno-
carcinoma carcinogenesis(16). The expression of the
wild or mutant p53 type seems to be slightly prevalent
in IAC negative for HPV by means of PCR analysis,
while p16INK4a expression, a potential marker for E7
function, is significantly related to IAC positive for
high-risk HPV(16). Conversely, the analysis of cyclin-
dependent kinase inhibitors may be useful for clinical
outcome; the combination of low expression of p27
(Kip1) and high p16INK4a expression strongly favors
a poor prognosis(17).
Herein, to test its sensitivity, we studied the occur-
rence of high-risk HPV infection as assessed by HC2
method in patients with uterine cervix IAC and ISAC
and compared it with other epithelial malignancies. To
exclude any factor that could lead to a false-negative
result, our research was initiated on surgical speci-
mens and the results were compared with results
obtained using samples taken directly from patients.
Materials and methods
Material for examination was brushed from surgical
specimens or collected directly from patients submit-
ted for surgical treatment at four hospitals, Arau´jo
Jorge Hospital, Cancer Hospital of Ana´polis, Centro
Materno Infantil, and Nascer Cidada˜o, and from the
Pathology Department of the School of Medicine of
the Federal University of Goia´s, Goiania, in Goias
State, Brazil, during the years 2002 and 2003. We also
investigated the frequency of high-risk HPV in squa-
mous malignant lesions to compare the frequencies of
HPV for both glandular and squamous lesions.
High-risk HPV was investigated using an HC2
assay. Samples were collected in two different ways:
first, directly from the lesion of surgical specimens
before fixation to allow the capture procedure. The
specimens were brushed directly and the samples
immediately placed in specimen transport medium
(STM) (Digene Co., Gaithersbourg, MD). Second, other
samples were collected directly from patients accord-
ing to the method suggested by instructions in the Di-
gene collection kit and placed in vials with universal
collection medium (UCM) from the Digene DNA-
Citoliq liquid-based cytology system (Digene Brasil,
Sa˜o Paulo, Brazil). These samples were also submitted
to cytologic examination, the data of which are not
presented in this paper.
The HC2 protocol was performed according to the
instructions of the manufacturer. In estimation of re-
sults, samples with a relative light unit .1 were con-
sidered positive. Only high-risk HPV types (16, 18, 31,
33, 35, 45, 51, 52, and 56) were tested. Briefly, after
sample denaturation, the DNA/RNA hybridization
step was performed and the hybrids were subse-
quently captured by anti-RNA/DNA antibody coated
onto the surface of microplate cavities. The immobi-
lized hybrids reacted with antihybrid antibody conju-
gated to alkaline phosphatase and were detected with
chemoluminescent substrate.
Results
A total of 113 cases of adenocarcinomas and related
lesions as well as 166 squamous lesions were ana-
lyzed. From these cases, 89 adenocarcinomas and 106
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squamous lesions were collected directly from surgical
specimens and placed in STM; the remaining 24
adenocarcinomas and 60 squamous lesions were col-
lected directly from the patients and placed in UCM.
Of the 113 glandular lesions, we observed 62 IAC, 8
ISAC, 26 IAC plus SCC, and 17 adenosquamous cells
carcinomas (ASCC). The high-risk HPV–positive reac-
tions were as follows: 51 (82.2%) in IAC, 8 (100%) in
ISAC, 25 (96.1%) in IAC plus SCC, and 14 (82.3%) in
ASCC. The squamous malignant lesions exhibited the
following capture assay for high-risk HPV results: 58
of 63 (89.0%) SCC and 94 of 103 in situ SCC (91.2%)
were positive for high-risk HPV. In our series, high-
risk HPV infection was quite similar for glandular and
squamous invasive malignant lesions, 86.7% and
91.5%, respectively. For in situ malignant lesions, HPV-
positive reactions were slightly less frequent in the
squamous lesions (91.2%) than in glandular lesions
(100%). The overall distribution of the positive high-
grade DNA-HPV testing and histopathologic classifi-
cation is shown in Table 1. Table 2 exhibits the distri-
bution of HC2 in different glandular and squamous
lesions in samples collected in STM. Importantly, the
DNA-HPV high-risk HC2 reaction was 100% positive
in ISAC of the cervix and 57.14% in adenosquamous
carcinoma. Additionally, Table 3 confirms the same
100% of DNA-HPV HC2-positive reactions in cases of
ISAC but shows 100% of HC2-positive reaction in
ASCC, as opposed to the samples directly collected
from the surgical specimens. Table 4 shows the distri-
bution of DNA-HPV high-risk status according to the
histologic subtypes of adenocarcinomas.
Discussion
The overall incidence of adenocarcinoma worldwide
has changed significantly during the past years, rang-
ing from 5% in five decades ago to 25% currently(18).
There is conclusive evidence that HPV infection is
a necessary cause to cervical cancer; however, the
discrepancy between the high frequency of HPV in-
fections among young, sexually active women and the
relative low incidence of cervical neoplasia is still to be
clearly understood(19).
HPV testing will presume increasing importance on
daily routine, although thoughtful evaluation of the re-
sults is strongly suggested, but analogously, it is well
accepted that it is highly specific in segregating true
squamous and glandular lesions from their mimics(20).
The results herein discussed clearly demonstrate the
strong association of in situ and invasive lesions with
high-grade HPV infection for both glandular and squa-
mous origins. In fact, the results of HPV testing
achieved in our study were remarkable since the ad-
enocarcinomas with HPV-related infections achieved
with PCR amplification range to 70%(21). For labo-
ratorial practices, the association of HPV testing in
cases where glandular lesions exhibit doubtful interpre-
tation should be seriously considered because cytology
lacks sensitivity and specificity in many circum-
stances(22). On the other hand, the DNA-HPV–positive
Table 1. General distribution of the positive reactions for
high-grade DNA-HPV in glandular malignancies and related
lesions and in squamous cell malignant lesions
Histologic diagnoses
Number
of cases
High grade
HPV–positive
reaction %
ISAC 8 8 100.0
Adenocarcinoma 62 51 82.2
Adenocarcinoma plus SCC 26 25 96.1
Adenosquamous carcinoma 17 14 82.3
Subtotal (lesions
with glandular component)
113 98 86.7
In situ SCC 103 94 91.2
Invasive SCC 63 58 89.0
Subtotal (squamous lesions) 166 152 91.5
Total ¼ 279 250 89.6
Table 2. Distribution of the high-grade DNA-HPV–positive
reactions in samples collected directly from the surgical speci-
mens with STM
Histologic
diagnoses
Number
of cases
HPV-
positive
cases
HPV-
negative
cases %
ISAC 5 5 0 100.00
Adenocarcinoma 58 47 11 81.03
Adenocarcinoma plus SCC 19 18 1 94.73
Adenosquamous carcinoma 7 4 3 57.14
In situ SCC 51 47 4 92.15
SCC 55 50 5 90.90
Total 95 171 24 87.69
Table 3. Distribution of the high-grade DNA-HPV–positive
reactions in samples collected from the patients with UCM
Histologic
diagnoses
Number
of cases
HPV-
positive
cases
HPV-
negative
cases %
ISAC 3 3 — 100.00
Adenocarcinoma 4 4 — 100.00
Adenocarcinoma
plus SCC
7 7 — 100.00
Adenosquamous
carcinoma
10 10 — 100.00
In situ SCC 52 47 5 90.38
SCC 8 7 1 87.50
Total 84 78 6 92.85
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HC2 reactions in SCC were slightly inferior to those ob-
tained with PCR; these frequently are close to 100%(23).
Conversely, HPV-associated infection in adenosqu-
amous lesion, believed to comprise around 50% of
cases(24), was higher in our study. Our findings are
quite similar to those of Pirog et al. (2000)(25) who used
a microdissection procedure to circumscribe the tissue
with the presumed alterations and evaluated the pres-
ence of HPV in these select fields with PCR assay. With
respect to DNA-HPV, they observed positive reactions
in 91% of adenocarcinomas and 100% of ASCC. Fur-
thermore, Ronnet et al. (1999)(26), using an HC2
method, found 100% positive DNA-HPV HC2 reaction
in cases of in situ carcinoma of the cervix. As a result,
the use of HC2 reaction and refined cytologic criteria
to improve the management of patients with glandular
atypia of undetermined significance was suggested(26).
Similar advisement was recently stated by Oliveira
et al. (2004)(27). These authors also found DNA-HPV–
positive reaction in 100% of ISAC, similar to our findings.
It is important to stress some points of our study:
first, we analyzed a large number of adenocarcinomas
and related lesions, more than 20 times those in pre-
vious studies(26,27). Second, we tested the hypothesis
that the sample collection for HC2 assay performed
directly on surgical specimens to be highly specific in
terms of quality than samples collected under routine
conditions. The material collected on the visible lesion
could constrain some variance in the HC2-positive
reaction in comparison to those collected directly from
patients. Surprisingly, the results obtained from the
samples collected from the patients were more fre-
quently positive to DNA-HPV than those achieved
from the samples collected directly from the surgical
specimens, even though they were not statistically sig-
nificant. The approach of taking samples directly from
the lesion of fresh surgical specimens certainly should
be more representative, but it was not. One possible
cause for these unexpected results could be due to the
use of iodine solution in presurgical proceedings that
can inhibit the HC2 reaction in some cases (informa-
tion from the manufacturer, Digene Manual—Hybrid
Capture II).
Another factor that may have contributed to the
inhibition of HC2 reaction in the surgical specimens,
especially in the cases of adenosquamous carcinoma,
is that some of the cases had been conized and others
subjected to previous radiotherapy, data that had not
been informed before collection of the material. An
additional important detail is that the adenocarcino-
mas collected from the patients were all of the endo-
metrioid or endocervical type; in the specimens, there
was one case of a minimal-deviation adenocarcinoma
and one case of a mesonephric adenocarcinoma, the
two referred as negative in the study of Pirog et al.(25).
One more possible source of bias could be the differ-
ent liquid mediums used in this study, although STM
and UCM are both produced by the same manufac-
turer and the performance of both mediums to iden-
tify HPV is similar(28).
As series involving adenocarcinomas are progres-
sively arising in surgical pathology routine, a critical
approach is necessary to understand the biologic
behavior of such lesions and to improve the parame-
ters for the diagnosis of such lesions as well as the dis-
crimination of related lesions. The first step, in our
view, is to determine the occurrence of HPV infection
in those lesions as determined by a molecular method
of routine use; other methods of recognized sensitivity
are feasible only for research purposes. Further
research in this field involves ongoing studies of our
group in an attempt to correlate cytologic parameters
of glandular and squamous lesions as well as molecu-
lar markers for the discrimination of cervical lesions
and their prognosis. Currently, we believe that HC2
method can be an important adjunct to, but not a sub-
stitute for, a properly done Pap smear.
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